To the Editor We read carefully the recent article by Pinnix et al1 about the treatment of patients with malignant lymphoma and Hodgkin lymphoma, which showed that standard treatment (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone [CHOP] or CHOP-like) administered to mothers with malignant lymphoma is well tolerated by the mother, without excessive toxicity, and with an excellent outcome (overall survival) compared with nonpregnant women who received the same treatment, as previously reported.2-4